❌

Normal view

Received β€” 16 July 2026 ⏭

GPC3-specific dnTGFΞ²RII-armoured CAR T cells for hepatocellular carcinoma

βœ‡Nature
By: Qi Zhang Β· Qihan Fu Β· Yinan Shen Β· Wanyue Cao Β· Gaowei Jin Β· Yize Zhang Β· Jiangchao Wu Β· Cao Chen Β· Hongkan Wang Β· Xingyuan Xu Β· Ke Sun Β· Xing Xue Β· Attilio Bondanza Β· Daisy Cao Β· Nina Chu Β· Nick Durham Β· Mark Cobbold Β· Benedetto Farsaci Β· Maria Letizia Giardino Torchia Β· Yixin Hao Β· Yi Hong Β· Jiaqi Huang Β· Michael Humphries Β· Qijie Jian Β· Gordon Moody Β· John Stone Β· Lingyan Sun Β· Eric Tu Β· Fei Wang Β· Fuzhe Wang Β· Ye Yang Β· Yihong Yao Β· Andy Zou Β· Xueli Bai Β· Tingbo Liang
15 July 2026 at 01:00

Nature, Published online: 15 July 2026; doi:10.1038/s41586-026-10786-z

Chimeric antigen receptor (CAR) T cells for antitumour therapy β€˜armoured’ with a dominant-negative TGFΞ² receptor II show enhanced efficacy and tolerable safety in patients with advanced hepatocellular carcinoma who have developed resistance or not responded to previous treatment.
❌